Search research articles
Contact Us
Filters
Showing results (71-80 of 154) with videos related to
Page
of 16
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 23, 2013
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Jürgen K Rockstroh, Edwin DeJesus, Keith Henry, et al.
HIV Clinical Trials
|
May 31, 2017
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI
Jose R Arribas, Edwin DeJesus, Jan van Lunzen, et al.
AIDS Research and Human Retroviruses
|
March 27, 2009
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758
Charles B Hicks, Edwin DeJesus, Louis M Sloan, et al.
Lancet (London, England)
|
July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
Edwin DeJesus, Jürgen K Rockstroh, Keith Henry, et al.
AIDS Research and Human Retroviruses
|
February 5, 2008
Adherence to enfuvirtide and its impact on treatment efficacy
Jürgen Rockstroh, Edwin Dejesus, Lucille Donatacci, et al.
JAMA
|
July 14, 2004
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
Joel E Gallant, Schlomo Staszewski, Anton L Pozniak, et al.
The Journal of Infectious Diseases
|
February 13, 2008
Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients
Jacob Lalezari, Gopal K Yadavalli, Michael Para, et al.
AIDS (London, England)
|
July 11, 2008
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
Roberto Ortiz, Edwin Dejesus, Homayoon Khanlou, et al.
The Lancet. HIV
|
February 22, 2017
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
Paul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 13, 2004
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial
Edwin DeJesus, Debra McCarty, Charles F Farthing, et al.
Page
of 16
Search research articles
Search
Showing results (71-80 of 154) with videos related to
Sort By:
Page
of 16
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 23, 2013
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Jürgen K Rockstroh, Edwin DeJesus, Keith Henry, et al.
HIV Clinical Trials
|
May 31, 2017
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI
Jose R Arribas, Edwin DeJesus, Jan van Lunzen, et al.
AIDS Research and Human Retroviruses
|
March 27, 2009
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758
Charles B Hicks, Edwin DeJesus, Louis M Sloan, et al.
Lancet (London, England)
|
July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
Edwin DeJesus, Jürgen K Rockstroh, Keith Henry, et al.
AIDS Research and Human Retroviruses
|
February 5, 2008
Adherence to enfuvirtide and its impact on treatment efficacy
Jürgen Rockstroh, Edwin Dejesus, Lucille Donatacci, et al.
JAMA
|
July 14, 2004
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial
Joel E Gallant, Schlomo Staszewski, Anton L Pozniak, et al.
The Journal of Infectious Diseases
|
February 13, 2008
Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients
Jacob Lalezari, Gopal K Yadavalli, Michael Para, et al.
AIDS (London, England)
|
July 11, 2008
Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48
Roberto Ortiz, Edwin Dejesus, Homayoon Khanlou, et al.
The Lancet. HIV
|
February 22, 2017
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial
Paul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 13, 2004
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial
Edwin DeJesus, Debra McCarty, Charles F Farthing, et al.
Page
of 16